American Cyanamid Company

Wyeth Holdings Corporation

American Cyanamid Compound

Yakov Gluzman

Joseph J Hlavka

Phaik-Eng Sum

Ving J Lee

Adma A Ross

Peter Bohlen

Andrew P Seddon

Beth A Rasmussen

Francis P Tally

Thomas Richard Jones

Viera P Muzithras

Michael R Ostrander

The invention is drawn to 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds of the formulawherein R, X, Rand Rare defined in the specification. The compounds of the invention are useful as broad spectrum antibiotics.

7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines

The disclosure is drawn to a method of using novel 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds to treat infections caused by a wide spectrum of bacterial organisms, including those which are resistant to tetracycline.

Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines

The present invention relates to methods for controlling and/or treating RNA-replicating viral infections which afflict human beings, animals and/or plants. Specifically, the RNA chain terminating agents, 3'-deoxyribouracil, 3'-deoxyriboguanine and 3'-deoxyribocytosine are useful in treating RNA-replicating viral infections.

Method for treating RNA viral infections by using RNA chain terminators

This invention relates to a method for identifying non-essential genes of the human cytomegalovirus (HCMV) genome through the insertion of a .beta.-glucuronidase marker gene into a specified HCMV gene, such that, if the product of the HCMV gene is not expressed, the gene is identified as non-essential for replication of HCMV. This invention also relates to a method of screening for compounds which inhibit HCMV by the insertion of the .beta.-glucuronidase marker gene into a HCMV gene, such that the enzyme marker is expressed and cleaves a conjugate chemical substrate in an assay system to yield a detectable fluorescing product or to result in a color change. This invention further provides the gene responsible in HCMV early cytopathic effect.

Human cytomegalovirus containing a .beta.-glucuronidase marker gene

Methods for identifying non-essential genes of the human cytomegalovirus

This invention is directed to the elucidation of DNA sequences encoding Class B beta-lactamase enzymes from Bacteroides fragilis and the amino acid sequences of those enzymes. This invention is also directed to screening methods for identifying antibiotics which are resistant to such beta-lactamase enzymes or for identifying compounds which inactivate such beta-lactamase enzymes.

DNA Sequences and amino acid sequences of class B beta-lactamase enzymes

Methods for screening class B beta-lactamase enzymes from Bacteroides

DNA sequences and amino acid sequences of class B beta lactamase enzymes

The disclosure is drawn to novel 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds. These compounds are useful to treat infections caused by a wide spectrum of bacterial organisms, including those which are resistant to tetracycline.

7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines

Method for treating bacterial infection with novel

The invention is drawn to 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds of the formula ##STR1## wherein R, X, R.sup.5 and R.sup.6 are defined in the specification. The compounds of the invention are useful as broad spectrum antibiotics.

Novel 9-amino-7-(substituted amino)-6-demethyl-6-deoxytetracyclines having activity against a wide spectrum of organisms including organisms which are resistant to tetracyclines are disclosed. Also disclosed are intermediates and methods for making the novel compounds of the present invention.

9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines

The present invention relates to novel chimeric fibroblast growth factors (FGF) wherein the alanine at amino acid 3 and serine 5 of native human recombinant basic fibroblast growth factor are replaced with glutamic acid. The N-terminus sequence of the present chimeric FGFs identify homology with that of human acidic fibroblast growth factor. The mitogenic properties of the native human recombinant basic FGF are exhibited by the present chimeric FGFs, and they are efficiently expressed in E. coli at significantly greater yields that previously reported. Novel variants of this new glu.sup.3,5 basic fibroblast growth factor, such as those in which cysteine 78 and cysteine 96 are replaced, e.g., with serine or other amino acids, to produce stabilized versions of the glu.sup.3,5 basic FGF and eliminate disulfide scrambled forms, are also described.

Growing community of inventors

Upper Saddle River, NJ, United States of America

Yakov Gluzman